Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720

Parasite Immunology

Volumn 29, Issue 10, 2007, Pages 525-533

  Saul, A ^a,f   Hensmann, M ^b   Sattabongkot, J ^c   Collins, W E ^d   Barnwell, J W ^d   Langermans, J A M ^b   Wu, Y ^a   Long, C A ^a   Dubovsky, F ^e   Thomas, A W ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^d NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^e PATH Malaria Vaccine Initiative   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Alhydrogel; Aluminium hydroxide; Montanide ISA 720; Plasmodium vivax; Pvs25H; Rhesus

Indexed keywords

ALUMINUM HYDROXIDE; ANTIBODY; ANTIGEN; IMMUNOLOGICAL ADJUVANT; MONTANIDE ISA 720; PROTEIN PVS25H; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BLOOD; CHIMPANZEE; CONTROLLED STUDY; EMULSION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOGENICITY; MALE; MOSQUITO; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM VIVAX; PRIORITY JOURNAL; RHESUS MONKEY;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANOPHELES; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ANTIGENS, SURFACE; FEMALE; HUMANS; MACACA MULATTA; MALARIA VACCINES; MALARIA, VIVAX; MALE; MANNITOL; OLEIC ACIDS; PLASMODIUM VIVAX; RANDOM ALLOCATION; RECOMBINANT PROTEINS;

MACACA MULATTA; PAN; PLASMODIUM VIVAX;

EID: 34648846388     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2007.00971.x     Document Type: Article

References (21)

1. Carter R, Mendis KN, Miller LH, Molineaux L Saul A. Malaria transmission-blocking vaccines - how can their development be supported? Nat Med 2000 6 : 241 244.
2. Hisaeda H, Stowers AW, Tsuboi T, et al. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect Immun 2000 68 : 6618 6623.
3. Sattabongkot J, Tsuboi T, Hisaeda H, et al. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates. Am J Trop Med Hyg 2003 69 : 536 541.
4. Malkin EM, Durbin AP, Diemert DJ, et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2005 23 : 3131 3138.
5. Pye D, Vandenberg KL, Dyer SL, et al. Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. Vaccine 1997 15 : 1017 1023.
6. Aucouturier J, Ganne V Laval A. Efficacy and safety of new adjuvants. Ann N Y Acad Sci 2000 916 : 600 604.
7. Collins WE, Barnwell JW, Sullivan JS, et al. Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees. Am J Trop Med Hyg 2006 74 : 215 221.
8. Saul A, Lawrence G, Smillie A, et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 1999 17 : 3145 3159.
9. Walther M, Dunachie S, Keating S, et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine 2005 23 : 857 864.
10. Toledo H, Baly A, Castro O, et al. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 2001 19 : 4328 4336.
11. Miles AP, Zhang Y, Saul A Stowers AW. Large-scale purification and characterization of malaria vaccine candidate antigen Pvs25H for use in clinical trials. Protein Expr Purif 2002 25 : 87 96.
12. Miles AP, McClellan HA, Rausch KM, et al. Montanide ISA720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine 2005 23 : 2530 2539.
13. van der Kolk M, de Vlas SJ, Saul A, et al. Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data. Parasitology 2005 130 : 13 22.
14. Miura K, Keister DB, Muratoua OV, et al. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. Malaria J 2007 6 : 107.
15. Hill AV. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol 1910 40 : iv vii.
16. Blandin S, Shiao SH, Moita LF, et al. Complement-like protein TEP1 is a determinant of vectorial capacity in the malaria vector Anopheles gambiae. Cell 2004 116 : 661 670.
17. Saul A. The mosquito's innate sting. Nat Med 2004 10 : 455 457.
18. Langermans JA, Schmidt A, Vervenne RA, et al. Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques. Vaccine 2005 23 : 4935 4943.
19. Aucouturier J, Dupuis L, Deville S, Ascarateil S Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002 1 : 111 118.
20. Genton B, Al-Yaman F, Anders R, et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 2000 18 : 2504 2511.
21. Genton B, Betuela I, Felger I, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 2002 185 : 820 827.